Market Place
Sourcing Support
All News #Library
Rare Diseases
BioMarin Presents VOXZOGO Achondroplasia Data at 2026 ACMG Meet
12 Mar 2026 //
PR NEWSWIRE
FDA Approves Biomarin`s PALYNZIQ For Adolescents With PKU
27 Feb 2026 //
PR NEWSWIRE
Biomarin Bet On Amicus To Ease Voxzogo`s Decline. Will It Work?
12 Feb 2026 //
BIOSPACE
Biomarin to Buy Amicus for $4.8 B in Rare Disease Bet
19 Dec 2025 //
PRESS RELEASE
FDA Reviews Biomarin`s Palynziq for Adolescent Phenylketonuria
29 Oct 2025 //
PR NEWSWIRE
Ascendis Prepares To Challenge Biomarin In Achondroplasia Amid
13 Oct 2025 //
BIOSPACE
BioMarin Reveals Phase 3 Data for in Phenylketonuria Teens
06 Sep 2025 //
PR NEWSWIRE
Spruce inks deal for BioMarin asset, plans 2026 approval filing
16 Apr 2025 //
FIERCE BIOTECH
U.S. FDA approves Catalyst Pharma`s rare disease drug
29 Nov 2018 //
REUTERS
BioMarin gets its shot at blockbuster as FDA OKs rare disease drug pegvaliase
25 May 2018 //
ENDPTS
Trulance, Yescarta head into the #FierceMadness Elite Eight
26 Mar 2018 //
FIERCE PHARMA
Judge forces NHS England rethink on Kuvan
09 Aug 2017 //
PMLIVE
European Commission Approves Brineura
01 Jun 2017 //
PR NEWSWIRE
First CLN2 Treatment Approved by EU
01 Jun 2017 //
RARE DR
BioMarin sees `high end` pricing on Brineura ahead of FDA decision
25 Apr 2017 //
FIERCE PHARMA
CHMP backs two rare disease therapies at April meeting
24 Apr 2017 //
PMLIVE
BioMarin`s Rare Disease Approval And Probiodrug`s Alzheimer`s Play
07 Apr 2017 //
SEEKINGALPHA
Clinical treatment for rare disorder phenylketonuria
22 Mar 2016 //
MEDICAL XPRESS
BioMarin Ph3 Study of Pegvaliase for PKU Meets Primary Endpoint
21 Mar 2016 //
GLOBENEWSWIRE
BioMarin sues to stop generic version of its $90K-a-year drug
06 Feb 2016 //
BIZ JOURNALS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.